Characterization of biomarkers to identify responders and non-responders in chronic spontaneous urticaria (CSU) therapy

Recruiting

• Conditions: Chronic spontaneous urticaria; L50.8; Other urticaria

• Registration Number: DRKS00024872
• Lead Sponsor: Klinik für DermatologeElbekliniken Stade-Buxtehude

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients with spontaneous urtikatia who are eligible for omalizumab therapy.

Exclusion Criteria

Subjects younger than 18 years and older than 65 years.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A panel of differentially expressed miRNAs can be identified in the blood plasma of different CSU patient groups.<br><br>A panel of differentially expressed miRNAs enables the identification of responders and non-responders as a predictive biomarker prior to initiation of omalizumab therapy.

Secondary Outcome Measures

Name	Time	Method
o endpoint